ABIVAX is trading 4.05% lower at €75.75; no confirmed new October 19 catalyst is provided. - The latest reported close was €78.95 on October 16, down 3.66%. - June 2 coverage tied investor concern to cancer cases alongside strong obefazimod Phase 3 ulcerative-colitis results; the company said the cases were unrelated to treatment. This is context, not a confirmed new catalyst.